nasdaq

Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

December 09, 2025 21:50 ET  | Source: Wave Life Sciences USA, Inc. CAMBRIDGE, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) --…

2 months ago

Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock

December 09, 2025 21:42 ET  | Source: Dyne Therapeutics, Inc. WALTHAM, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc.…

2 months ago

Iridium Appoints Louis Alterman to Board of Directors

MCLEAN, Va., Dec. 4, 2025 /PRNewswire/ -- Iridium Communications Inc. (Nasdaq: IRDM), a leading provider of global voice, data, and…

2 months ago

Iridium Awarded 5-Year System Infrastructure Transformation and Hybridization Contract Worth Up to $85.8 Million

New Contract Supports Enhancements to the Iridium and U.S. DoD EMSS Service Center and Related FacilitiesMCLEAN, Va., Dec. 2, 2025…

2 months ago

Global Mofy AI Limited Announces US$4.8 Million Private Placement Financing

BEIJING, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Global Mofy AI Limited (the “Company” or “Global Mofy”) (Nasdaq: GMM), a generative…

2 months ago

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 05, 2025 08:00 ET  | Source: UroGen Pharma Ltd. PRINCETON, N.J., Dec. 05, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma…

2 months ago

Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT for Parkinsons Disease

December 05, 2025 08:00 ET  | Source: Amneal Pharmaceuticals LLC Interim data show substantial improvements in “Good On” time compared…

2 months ago

PDF Solutions to Make Its Analyst Day Webcast and Presentation Available

Company Also Reaffirms 2025 Financial Outlook  December 01, 2025 19:01 ET  | Source: PDF Solutions, Inc. SANTA CLARA, Calif., Dec.…

2 months ago

Fusemachines Files Q3 2025 Quarterly Report and Discloses Nasdaq Notice

November 28, 2025 16:05 ET  | Source: Fusemachines NEW YORK, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Fusemachines Inc. (“Fusemachines” or…

2 months ago

Eisai Submits New Drug Application for Subcutaneous Formulation of LEQEMBI for the Treatment of Early Alzheimers Disease in Japan

If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the…

2 months ago